Corporate | 29 March 2012 17:31

Cytos invites for the Annual Shareholders’ Meeting 2012

Cytos Biotechnology AG / Key word(s): AGM/EGM

29.03.2012 / 17:31

Schlieren (Zurich), Switzerland, 29 March, 2012 – Cytos Biotechnology Ltd ('Cytos'), today announced that the Annual Shareholders' Meeting 2012 will take place on Friday, April 20, 2012 at 3 p.m. at Cytos' offices in Schlieren/Zurich (Switzerland).

In addition to the ordinary agenda items, the shareholders are also invited to vote on the recapitalization as announced on March 21, 2012 and in particular on the capital increase. The invitation as well as the agenda items including detailed information about the recapitalization can be found on the following website: http://www.cytos.com/userfiles/file/AGM_2012.pdf

For further information please contact:

Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel.: +41 44 733 46 46
e-Mail: harry.welten@cytos.com
Website: www.cytos.com

About Cytos Biotechnology Ltd
Cytos Biotechnology Ltd is a Swiss public biotechnology company that specializes in the development and commercialization of a new class of biopharmaceutical products – the Immunodrugs(TM). Immunodrugs(TM) are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs(TM) are designed to instruct the patient's immune system to produce the desired therapeutic antibody or T cell responses that modulate chronic disease processes. Cytos' Immunodrug(TM) candidates are being developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Cytos Biotechnology Ltd is listed on the main segment of the SIX Swiss Exchange Ltd under the symbol CYTN.

This foregoing press release may contain forward-looking statements that include words or phrases such as 'are intended for', 'are designed to', or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.

End of Corporate News

29.03.2012 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital market and press releases.
The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies.
The Swiss news archive can be found at http://www.equitystory.ch/nachrichten

Language:	English
Company:	Cytos Biotechnology AG
	Wagistr. 25
	8952 Schlieren
	Switzerland
Phone:	+41 44 733 4747
Fax:	+41 44 733 4740
E-mail:	info@cytos.com
Internet:	www.cytos.com
ISIN:	CH0011025217, CH0029060735
Swiss Security Number:	–
Listed:	Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt; SIX

End of News EquityStory AG News-Service

163087  29.03.2012